Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

So Far, PCSK9 Inhibitors Work for All Heterozygous FH Patients.

McNutt MC, Ahmad Z.

Circ Cardiovasc Genet. 2015 Dec;8(6):749-51. doi: 10.1161/CIRCGENETICS.115.001256. No abstract available.

2.

Hepatic ANGPTL3 regulates adipose tissue energy homeostasis.

Wang Y, McNutt MC, Banfi S, Levin MG, Holland WL, Gusarova V, Gromada J, Cohen JC, Hobbs HH.

Proc Natl Acad Sci U S A. 2015 Sep 15;112(37):11630-5. doi: 10.1073/pnas.1515374112. Epub 2015 Aug 24.

3.

Antagonism of secreted PCSK9 increases low density lipoprotein receptor expression in HepG2 cells.

McNutt MC, Kwon HJ, Chen C, Chen JR, Horton JD, Lagace TA.

J Biol Chem. 2009 Apr 17;284(16):10561-70. doi: 10.1074/jbc.M808802200. Epub 2009 Feb 17.

4.

Plasma PCSK9 preferentially reduces liver LDL receptors in mice.

Grefhorst A, McNutt MC, Lagace TA, Horton JD.

J Lipid Res. 2008 Jun;49(6):1303-11. doi: 10.1194/jlr.M800027-JLR200. Epub 2008 Mar 19.

5.

Molecular basis for LDL receptor recognition by PCSK9.

Kwon HJ, Lagace TA, McNutt MC, Horton JD, Deisenhofer J.

Proc Natl Acad Sci U S A. 2008 Feb 12;105(6):1820-5. doi: 10.1073/pnas.0712064105. Epub 2008 Feb 4.

6.

Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells.

McNutt MC, Lagace TA, Horton JD.

J Biol Chem. 2007 Jul 20;282(29):20799-803. Epub 2007 May 29.

7.

Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice.

Lagace TA, Curtis DE, Garuti R, McNutt MC, Park SW, Prather HB, Anderson NN, Ho YK, Hammer RE, Horton JD.

J Clin Invest. 2006 Nov;116(11):2995-3005.

8.

Human promoter genomic composition demonstrates non-random groupings that reflect general cellular function.

McNutt MC, Tongbai R, Cui W, Collins I, Freebern WJ, Montano I, Haggerty CM, Chandramouli G, Gardner K.

BMC Bioinformatics. 2005 Oct 18;6:259.

9.

Pharmacologic profiling of transcriptional targets deciphers promoter logic.

Freebern WJ, Haggerty CM, Montano I, McNutt MC, Collins I, Graham A, Chandramouli GV, Stewart DH, Biebuyck HA, Taub DD, Gardner K.

Pharmacogenomics J. 2005;5(5):305-23.

PMID:
16044165
10.

Kinetic profiles of p300 occupancy in vivo predict common features of promoter structure and coactivator recruitment.

Smith JL, Freebern WJ, Collins I, De Siervi A, Montano I, Haggerty CM, McNutt MC, Butscher WG, Dzekunova I, Petersen DW, Kawasaki E, Merchant JL, Gardner K.

Proc Natl Acad Sci U S A. 2004 Aug 10;101(32):11554-9. Epub 2004 Jul 30.

11.

The Arthus reaction in domestic cats.

Kier AB, McDonnell JJ, Stern A, McNutt MC.

Vet Immunol Immunopathol. 1988 Apr;18(3):229-35.

PMID:
2969157

Supplemental Content

Loading ...
Support Center